Aradigm

This page shows the latest Aradigm news and features for those working in and with pharma, biotech and healthcare.

FDA panel rejects Aradigm/Grifols’ inhaled antibiotic

Aradigm has been unable to convince an FDA advisory committee that that its inhaled version of ciprofloxacin should be approved for chronic infections in patients with a serious lung disease. ... It paid Aradigm a $5m milestone last September after the

Latest news

Sanofi abandons inhaled insulin pact with Mannkind

The disappointing performance of the drug also promoted other inhaled insulin developers - including Eli Lilly/Alkermes and Novo Nordisk/Aradigm to discontinue their own programmes.
Sanofi launches inhaled insulin in US

The problems faced by Pfizer also prompted Lilly/Alkermes and Novo Nordisk/Aradigm to discontinue their own programmes, despite reaching the phase III testing stage.
MannKind's inhaled insulin backed for US approval

The problems faced by Pfizer also prompted Lilly/Alkermes and Novo Nordisk/Aradigm to discontinue their own programmes, despite reaching the phase III testing stage.
MannKind celebrates as inhaled insulin clears pivotal trials

Pfizer took a $2.8bn pretax hit on the product, and its demise also prompted other companies developing inhaled insulin - Lilly/Alkermes and Novo Nordisk/Aradigm - to drop their own programmes.
Court denies Novo Nordisk injunction against Exubera

Novo Nordisk developed the product with US drug delivery firm, Aradigm.

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

Rethinking our approach to infectious disease preparedness

Achaogen and Aradigm filed for bankruptcy in 2019, and Melinta did the same at the start of 2020, despite heavy investment from the US Biomedical Advanced Research and Development Authority (BARDA).
Going the distance

The companies have already succeeded where ill-fated programmes from Lilly/Alkermes and Novo Nordisk/Aradigm failed, but it must now prove it can do better than Pfizer's Exubera, launched
Deal Watch table for May 2013

220. Therasphere/ BTG. Asset purchase. Treatment for liver cancer. 200. Aradigm/ Grifols . ... Licence equity. Inhaled ciprofloxacin phase III ready. 35 per cent of Aradigm ($26m).